These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29129444)

  • 41. Biomarkers in pancreatic ductal adenocarcinoma.
    Gallego J; López C; Pazo-Cid R; López-Ríos F; Carrato A
    Clin Transl Oncol; 2017 Dec; 19(12):1430-1437. PubMed ID: 28616721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
    Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
    Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
    Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma.
    Swords DS; Mulvihill SJ; Firpo MA; Scaife CL
    JAMA Oncol; 2018 Aug; 4(8):1129-1130. PubMed ID: 30003235
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors influencing receipt of adjuvant chemotherapy after surgery for pancreatic cancer: a two-center retrospective cohort study.
    Åkerberg D; Björnsson B; Ansari D
    Scand J Gastroenterol; 2017 Jan; 52(1):56-60. PubMed ID: 27598522
    [TBL] [Abstract][Full Text] [Related]  

  • 46. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.
    Martinez-Useros J; Georgiev-Hristov T; Fernández-Aceñero MJ; Borrero-Palacios A; Indacochea A; Guerrero S; Li W; Cebrián A; Gómez Del Pulgar T; Puime-Otin A; Del Puerto-Nevado L; Rodríguez-Remírez M; Pérez N; Celdrán A; Gebauer F; Garcia-Foncillas J
    PLoS One; 2017; 12(8):e0182044. PubMed ID: 28763470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer.
    Kim S; Kang M; Lee S; Bae S; Han S; Jang JY; Park T
    Biomed Eng Online; 2014; 13 Suppl 2(Suppl 2):S5. PubMed ID: 25560450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cystic papillary pattern in pancreatic ductal adenocarcinoma: a heretofore undescribed morphologic pattern that mimics intraductal papillary mucinous carcinoma.
    Kelly PJ; Shinagare S; Sainani N; Hong X; Ferrone C; Yilmaz O; Fernández-del Castillo C; Lauwers GY; Deshpande V
    Am J Surg Pathol; 2012 May; 36(5):696-701. PubMed ID: 22367300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pancreatectomy combined with superior mesenteric-portal vein resection: report of 32 cases.
    Zhou GW; Wu WD; Xiao WD; Li HW; Peng CH
    Hepatobiliary Pancreat Dis Int; 2005 Feb; 4(1):130-4. PubMed ID: 15730937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer.
    Bronsert P; Kohler I; Timme S; Kiefer S; Werner M; Schilling O; Vashist Y; Makowiec F; Brabletz T; Hopt UT; Bausch D; Kulemann B; Keck T; Wellner UF
    Surgery; 2014 Jul; 156(1):97-108. PubMed ID: 24929761
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols.
    Berardi R; Verdecchia L; Scartozzi M; Cascinu S
    JOP; 2005 Jan; 6(1 Suppl):118-21. PubMed ID: 15650296
    [No Abstract]   [Full Text] [Related]  

  • 52. Three-year and five-year outcomes of surgical resection for pancreatic ductal adenocarcinoma: Long-term experiences in one medical center.
    Hsu CP; Hsu JT; Liao CH; Kang SC; Lin BC; Hsu YP; Yeh CN; Yeh TS; Hwang TL
    Asian J Surg; 2018 Mar; 41(2):115-123. PubMed ID: 28010955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer.
    Guo M; Luo G; Liu C; Cheng H; Lu Y; Jin K; Liu Z; Long J; Liu L; Xu J; Huang D; Ni Q; Yu X
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: Long-term oncologic outcomes after standard resection.
    Sahakyan MA; Kim SC; Kleive D; Kazaryan AM; Song KB; Ignjatovic D; Buanes T; Røsok BI; Labori KJ; Edwin B
    Surgery; 2017 Oct; 162(4):802-811. PubMed ID: 28756944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peroral pancreatoscopy using the SpyGlass system for the assessment of intraductal papillary mucinous neoplasm of the pancreas.
    Nagayoshi Y; Aso T; Ohtsuka T; Kono H; Ideno N; Igarashi H; Takahata S; Oda Y; Ito T; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):410-7. PubMed ID: 24123930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic markers in pancreatic ductal adenocarcinomas.
    Hezel AF; Bardeesy N
    Cancer Biol Ther; 2008 Sep; 7(9):1360-1. PubMed ID: 18836287
    [No Abstract]   [Full Text] [Related]  

  • 58. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.
    Stelow EB; Shaco-Levy R; Bao F; Garcia J; Klimstra DS
    Am J Surg Pathol; 2010 Apr; 34(4):510-8. PubMed ID: 20182344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.
    Tsutsumi S; Morohashi S; Kudo Y; Akasaka H; Ogasawara H; Ono M; Takasugi K; Ishido K; Hakamada K; Kijima H
    J Surg Oncol; 2011 Jun; 103(7):669-73. PubMed ID: 21360711
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.